{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=1+X+10%5E6+cells%2Fkg", "query": { "intervention": "1 X 10^6 cells/kg" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 281, "total_pages": 29, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=1+X+10%5E6+cells%2Fkg&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-02T09:18:15.404Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01875237", "title": "Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia", "Myeloma", "Myeloproliferative Diseases" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Stem Cell infusion", "type": "PROCEDURE" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mini Methotrexate", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "Donor Lymphocyte Infusion (DLI)", "type": "PROCEDURE" }, { "name": "AP1903", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Questionnaire", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BEHAVIORAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 3, "start_date": "2013-12-27", "completion_date": "2017-03-07", "has_results": true, "last_update_posted_date": "2019-07-16", "last_synced_at": "2026-10-02T09:18:15.404Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01875237" }, { "nct_id": "NCT00697684", "title": "Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Myelodysplastic Syndrome", "Acute Lymphocytic Leukemia", "Relapsed/Refractory Chronic Lymphocytic Leukemia", "Relapsed/Refractory Non Hodgkin's Lymphoma", "Hodgkins Disease", "Relapsed Refractory Multiple Myeloma" ], "interventions": [ { "name": "Antithymocyte Globulin", "type": "DRUG" }, { "name": "Clofarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 29, "start_date": "2008-06", "completion_date": "2023-11", "has_results": false, "last_update_posted_date": "2023-11-28", "last_synced_at": "2026-10-02T09:18:15.404Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00697684" }, { "nct_id": "NCT01218867", "title": "CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Cancer", "Metastatic Melanoma", "Renal Cancer" ], "interventions": [ { "name": "Anti-VEGFR2 CAR CD8 plus PBL", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Aldesleukin", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 24, "start_date": "2010-11-10", "completion_date": "2015-12-15", "has_results": true, "last_update_posted_date": "2019-12-10", "last_synced_at": "2026-10-02T09:18:15.404Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01218867" }, { "nct_id": "NCT01586403", "title": "Transfer of Genetically Engineered Lymphocytes in Melanoma Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Dose 1", "type": "BIOLOGICAL" }, { "name": "Dose 2", "type": "BIOLOGICAL" }, { "name": "Dose 3", "type": "BIOLOGICAL" }, { "name": "Dose 4", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Loyola University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2012-07", "completion_date": "2028-09", "has_results": false, "last_update_posted_date": "2020-10-30", "last_synced_at": "2026-10-02T09:18:15.404Z", "location_count": 1, "location_summary": "Maywood, Illinois", "locations": [ { "city": "Maywood", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01586403" }, { "nct_id": "NCT03085173", "title": "A Trial of \"Armored\" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia (CLL)", "Relapsed", "Refractory" ], "interventions": [ { "name": "EGFRt/19-28z/4-1BBL CAR T cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2017-03-15", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2026-04-07", "last_synced_at": "2026-10-02T09:18:15.404Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03085173" }, { "nct_id": "NCT05976555", "title": "Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "BCMA-TGFβ CAR-T cells (0.50 x 10^6 cells/kg)", "type": "BIOLOGICAL" }, { "name": "BCMA-TGFβ CAR-T cells (0.75 x10^6 cells/kg)", "type": "BIOLOGICAL" }, { "name": "BCMA-TGFβ CAR-T cells (1 x 10^6 cells/kg)", "type": "BIOLOGICAL" }, { "name": "BCMA-TGFβ CAR-T cells (2.5 x 10^6 cells/kg)", "type": "BIOLOGICAL" }, { "name": "Maximum tolerated dose", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 30, "start_date": "2026-05-15", "completion_date": "2029-05", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-10-02T09:18:15.404Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05976555" }, { "nct_id": "NCT05286255", "title": "Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "COVID-19 Pneumonia", "Viral Pneumonia" ], "interventions": [ { "name": "Allogeneic Mesenchymal Stromal Cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Medical University of South Carolina", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 0, "start_date": "2024-10-01", "completion_date": "2024-10-01", "has_results": false, "last_update_posted_date": "2024-10-30", "last_synced_at": "2026-10-02T09:18:15.404Z", "location_count": 1, "location_summary": "Charleston, South Carolina", "locations": [ { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05286255" }, { "nct_id": "NCT06959771", "title": "Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "CD40L-HyperIgM Syndrome" ], "interventions": [ { "name": "Base-edited hematopoietic stem and progenitor cells", "type": "BIOLOGICAL" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Palifermin", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Base-edited T lymphocyte cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "37 Years", "maximum_age": "120 Years", "sex": "MALE", "summary": "37 Years to 120 Years · Male only" }, "enrollment_count": 1, "start_date": "2025-07-16", "completion_date": "2027-10-28", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-02T09:18:15.404Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06959771" }, { "nct_id": "NCT00057954", "title": "Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Extracorporeal Photopheresis", "type": "PROCEDURE" }, { "name": "Pentostatin", "type": "DRUG" }, { "name": "Total body irradiation (TBI)", "type": "RADIATION" }, { "name": "Allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "Cyclosporin (CSA)", "type": "DRUG" }, { "name": "Mycophenolate mofetil (MMF)", "type": "DRUG" }, { "name": "Methotrexate (MTX)", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2005-11-09", "completion_date": "2011-05", "has_results": true, "last_update_posted_date": "2023-06-28", "last_synced_at": "2026-10-02T09:18:15.404Z", "location_count": 19, "location_summary": "Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 12 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00057954" }, { "nct_id": "NCT03171194", "title": "Pilot Trial of Mesenchymal Stem Cells for Systemic Lupus Erythematosus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "System; Lupus Erythematosus" ], "interventions": [ { "name": "Low Dose Mesenchymal Stem Cells (MSCs)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical University of South Carolina", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 6, "start_date": "2017-04-27", "completion_date": "2018-10-25", "has_results": false, "last_update_posted_date": "2019-05-02", "last_synced_at": "2026-10-02T09:18:15.404Z", "location_count": 2, "location_summary": "Atlanta, Georgia • Charleston, South Carolina", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03171194" } ] }